<DOC>
	<DOCNO>NCT00745875</DOCNO>
	<brief_summary>The aim study collect initial efficacy safety data use new treatment ZD4054 ( Zibotentan ) use combination pemetrexed ( standard chemotherapy agent ) treatment non-small cell lung cancer compare treatment pemetrexed alone</brief_summary>
	<brief_title>ZD4054 ( Zibotentan ) Phase II Non-Small Cell Lung Cancer Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically cytologically confirm locally advanced metastatic NSCLC entry study suitable pemetrexed therapy Patients meet one follow criterion : progress follow one prior platinumbased chemotherapy regimen locally advance metastatic disease ; progress within 6 month adjuvant platinumbased chemotherapy Life expectancy &gt; 12 week Prior treatment pemetrexed last 12 month . Prior therapy ET receptor antagonist Any recent surgery , unhealed surgical incision , severe concomitant medical condition ( eg , unstable cardiac , hepatic renal disease ) significant laboratory finding make undesirable patient participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Phase II</keyword>
	<keyword>ZD4054</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Lung Cancer</keyword>
</DOC>